Clinical Trials Logo

Recurrent Solid Tumors clinical trials

View clinical trials related to Recurrent Solid Tumors.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06161493 Recruiting - Ovarian Cancer Clinical Trials

ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

Start date: January 23, 2024
Phase: Phase 1
Study type: Interventional

This Phase I, open label, dose determining study of oral niraparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with metastatic or recurrent solid cancer. Dose escalation will follow the mTPI-2/Keyboard design. Eligible patients will receive therapy until disease progression or unacceptable toxicities are experienced.

NCT ID: NCT06031441 Recruiting - Clinical trials for Metastatic Solid Tumors

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Start date: November 27, 2023
Phase: Phase 1
Study type: Interventional

This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion.